Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Sermorelin | Reviews, Clinical Trials, and Safety

Sermorelin | Reviews, Clinical Trials, and Safety Sermorelin is a synthetic peptide that stimulates the body to produce more growth hormone, associated with benefits like fat loss, improved body composition, longevity, and more. Compound Overview Class of Comp

Sermorelin | Reviews, Clinical Trials, and Safety

Sermorelin is a synthetic peptide that stimulates the body to produce more growth hormone, associated with benefits like fat loss, improved body composition, longevity, and more.

Compound Overview

Class of Compound

Peptide

Mechanism of Action:

As an analogue of growth hormone-releasing hormone, sermorelin binds to the growth hormone-releasing hormone receptor of the anterior pituitary gland, thus stimulating the secretion of growth hormone.

Notable Studies:

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency

Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

A potentially effective drug for patients with recurrent glioma: sermorelin

Also Known As:

Geref, Gerel, sermorelin acetate, 114466-38-5, UNII-00IBG87IQW

Research Applications:

GH regulation

Muscle growth and recovery

Anti-aging

Risks:

Lack of long-term data

No longer FDA approved

Banned by WADA

Chemical Structure

What is Sermorelin?

Sermorelin is a synthetic peptide analogue of human growth hormone-releasing hormone (GHRH). It was developed by the German firm EMD Serono for the treatment of growth hormone deficiency (GHD) in both children and adults. The peptide’s primary function is to stimulate the manufacture and release of growth hormone (GH) in the human body.

Following clinical trials, sermorelin was initially approved by the U.S. Food and Drug Administration (FDA) in 1997 and sold under the trade name “Geref,” indicated for the treatment of growth hormone deficiency (GHD) in both children and adults [1, 2]. Its FDA approval was discontinued in 2008 for commercial reasons unrelated to its safety or efficacy [3].

Sermorelin was also used as a diagnostic agent for assessing whether a given patient’s pituitary gland was functioning properly and releasing adequate amounts of GH [1, 2].

The peptide is now being researched for applications beyond the diagnosis and treatment of hormone deficiency, including for its role in sleep quality, heart health, and even as a novel brain tumor treatment.

What Does Sermorelin Do?

Sermorelin contains the first 29 amino acids of growth hormone-releasing hormone and is the shortest synthetic peptide to offer the full biological activity of endogenous GHRH [4].

As an analog of GHRH, sermorelin also binds to the growth hormone-releasing hormone receptor found in the anterior pituitary gland, signaling to the pituitary gland to produce and release more growth hormone in the body, by way of somatotropic cells.

Sermorelin’s mechanism is different from that of biosynthetic hGH, since injection of the latter can raise GH in the body to supraphysiological levels. On the other hand, the primary function of sermorelin is to mimic native GRF and stimulate GH secretion to the maximum natural level. [4].

Sermorelin Benefits | Clinical Trials

Our team conducted a literature review using PubMed, Google Scholar, and EMBASE to identify the relevant benefits and uses of sermorelin. Here are three of the most notable:

Effective treatment of adult-onset growth hormone insufficiency: Sermorelin is an effective and attractive treatment of adult-onset GH insufficiency. Unlike rhGH, sermorelin does not stimulate IGF-1 production in the liver and instead stimulates the pituitary gland to produce and secrete endogenous hGH, giving it a number of clinical advantages over exogenous hGH.

Notably, according to a 2006 article by Richard Walker, overdoses of endogenous hGH are “difficult if not impossible to achieve” as the effects of sermorelin are regulated by negative feedback involving the inhibitory neurohormone, somatostatin.

Sermorelin is not associated with the pro-cancer and pro-diabetes side effects linked to long-term hGH therapy, and is thus heavily researched to treat adult-onset GH insufficiency along with being used in longevity medicine for preserving youthful anatomy and physiology [5].

Positive effects on body composition: Sermorelin has been identified as one of several growth hormone secretagogues (GHS) that can help manage body composition in hypogonadal males. In a 2020 paper, Deepankar et al. noted that sermorelin can “significantly improve body composition” (in hypogonadal males) while “ameliorating specific hypogonadal symptoms” such as fat gain and muscular atrophy [6].

While the authors suggest that sermorelin could be used to achieve lean mass gain in both hypogonadal males and men with subclinical hypogonadism, to date, there is no published research that has investigated sermorelin’s effect on body composition in healthy subjects, highlighting an area for further research.

Potential anti-aging benefits: A 1992 study identified sermorelin’s potential anti-aging benefits after nine young male test subjects (22 to 33 years old) and ten elderly male test subjects (60 to 78 years old) were administered the peptide. The study found that short-term subcutaneous sermorelin injections enabled healthy male test subjects to reverse age-related decreases in GH and levels of IGF-I [7].

A 1997 single-blind randomized placebo-controlled trial found that elderly male and female test subjects who received nightly subcutaneous injections of sermorelin for 16 weeks experienced a “significant increase in skin thickness.” The peptide was found to produce significant increases in lean body mass in male test subjects and notable increases in libido and wellbeing. Male test subjects gained an average of 1.26 kg of lean body mass by the end of the trial [8]

Sermorelin and heart health: Sermorelin has been investigated alongside other GHRH agonists as a potential treatment for myocardial infarction scarring in swine [9]. The 2015 study found that sermorelin offered a number of benefits in post-heart attack animal models, which included:

Reduced remodeling following a heart attack

Increased growth of blood vessels in damaged tissue

Reduction in cell death in cardiomyocytes

As a result, there is research interest in sermorelin’s heart health-related benefits, namely in its potential to treat problems resulting from cardiac remodeling and ability to heal damage in myocytes following a heart attack.

Buy Sermorelin from our top-rated vendor...

Sermorelin Side Effects

According to a review of sermorelin’s use in the diagnosis and treatment of children with GHD, once daily subcutaneous doses of the peptide were well tolerated [4]. The review noted that the most commonly reported adverse events were transient facial flushing and injection site pain.

According to Drugs.com, the most common sermorelin side effects are [10]:

Facial flushing

Headache

Nausea

Pain

Redness, or swelling at injection site

Paleness

Strange taste in mouth

Vomiting

Is Sermorelin Safe?

Sermorelin currently lacks FDA approval as its approval was withdrawn in 2008 for reasons other than safety and efficacy [3]. Data on the safety of sermorelin for non-medical uses such as improving body composition in healthy subjects remains lacking.

As noted by Prakash and Goa, while sermorelin is a “well-tolerated” GHRH analogue when used as a provocative test of GHD in children, such tests would involve a single intravenous 1 μg/kg body weight dose and tell us very little about the peptide’s long-term safety [4].

According to Walker, sermorelin is potentially safer than exogenous rhGH because it does not stimulate IGF-1 and is virtually incapable of causing overdose, given that the peptide merely stimulates endogenous hGH and its effects are regulated by somatostatin [5].

Sermorelin Dosage Calculator

Research suggests that sermorelin is commonly administered at doses starting from 100-200 mcg per day for objectives like improved body composition, often in combination with other growth hormone secretagogues such as ipamorelin.

When used in longevity research, sermorelin is typically cycled for three to six months.

In terms of timing, Prakash and Goa’s research indicates that in the diagnosis and treatment of GH deficiency in children, it was common to administer sermorelin at night before bed, at least two hours after eating, or first thing in the morning when endogenous GH levels are typically at their peak.

Where to Buy Sermorelin Online? | 2024 Edition

Researchers looking to source high-quality sermorelin online should turn to our top recommended vendor:

Xcel Peptides

Xcel Peptides is a US-based vendor that offers research-grade sermorelin in 5mg vials for $40 per unit.

We fully endorse this vendor for the following reasons:

Quality Assurance: Xcel Peptides has a rigorous quality control program in place to ensure that all of its peptides are up to standard. They source their peptides from cGMP approved manufacturers.

Fast Shipping: Xcel Peptides offers fast shipping for free on domestic orders over $200. Orders generally arrive in 2-5 business days.

High-Quality Information: The vendor’s website includes detailed research summaries of each peptide up for sale, as well as articles on how to properly handle peptides and more.

To obtain high-quality sermorelin and other peptides, head directly to Xcel Peptides.

FAQ

Sermorelin typically comes in the form of powder and must be reconstituted using bacteriostatic or sterile water.

After being reconstituted, sermorelin is administered subcutaneously.

Follow all standard safety precautions when reconstituting sermorelin, including wiping the tops of vials with alcohol and avoiding contact with the syringe used to pull the bacteriostatic or sterile water. To properly reconstitute the peptide solution, drip the reconstituting liquid down the side of the peptide vial and let the solution dissolve on its own.

Qualified researchers may buy sermorelin online as a reference material for research purposes. In the domain of competitive sport, it is important to note that sermorelin and other growth hormone-releasing hormone analogs are banned by the World Anti-Doping Agency [11, 12].

Non-qualified researcher or laboratory professionals are generally advised to refrain from purchasing and handling sermorelin.

Sermorelin is no longer FDA-approved, and researchers should note the lack of long-term clinical studies involving sermorelin as a risk of administration. However, our systematic review of the available safety data has indicated that this peptide is generally well-tolerated with few to no long-term side effects in individuals with no pre-existing risk factors.

Yes, it is. Sermorelin was approved for the treatment and diagnosis of GHD deficiency in subjects of all ages by the U.S. Food and Drug Administration (FDA) in 1997, and its approval was discontinued in 2008 for reasons unrelated to safety and effectiveness [1, 2, 3]. Research indicates that sermorelin peptide is an effective growth hormone secretagogue that significantly increases levels of hGH in the body in both children and adults [4, 13]. Sermorelin has also shown promise in other clinical contexts, including muscle wasting in elderly people with GH insufficiency, lipodystrophy in HIV-infected patients, and impaired cognition in elderly subjects [14]. A breakthrough study in 2021 has identified sermorelin as a promising treatment for patients with recurrent glioma, a common type of brain tumor [15].

No, sermorelin is not an anabolic-androgenic steroid. It is a peptide analog of growth hormone-releasing hormone.

No, sermorelin does not act to boost testosterone production.

Yes, as a growth hormone-releasing hormone analog, sermorelin is associated with the same effects as hGH therapy, including increased muscle mass.

No, in published studies to date, sermorelin has not been found to cause weight gain. In fact, a primary benefit of sermorelin is its ability to reduce adipose tissue, thereby producing weight loss.

Sermorelin | Reviews

Sermorelin has an array of both proven and potential benefits and uses, and may be used to improve body composition, achieve anti-aging benefits, and promote heart health.

The peptide has been approved by the FDA, and is backed by extensive literature that establishes it as an attractive alternative to hGH therapy.

To purchase sermorelin online, we recommend the vendor with the purest peptides and most secure buying experience online.

References

Xu, Z. (2016). Growth Hormone-Releasing Hormone. In Handbook of Hormones (pp. 144-e18B). Academic Press.

US Food and Drug Administration, (n.d.). Drugs at FDA: FDA-Approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443

Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. (2021). Retrieved 3 June 2021, from https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams

Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999 Aug;12(2):139-57. doi: 10.2165/00063030-199912020-00007. PMID: 18031173.

Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. doi: 10.2147/ciia.2006.1.4.307. PMID: 18046908; PMCID: PMC2699646.

Sinha, Deepankar K et al. “Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.” Translational andrology and urology vol. 9,Suppl 2 (2020): S149-S159. doi:10.21037/tau.2019.11.30

Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992 Aug;75(2):530-5. doi: 10.1210/jcem.75.2.1379256. PMID: 1379256.

Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997 May;82(5):1472-9. doi: 10.1210/jcem.82.5.3943. PMID: 9141536.

Bagno, L. L., Kanashiro‐Takeuchi, R. M., Suncion, V. Y., Golpanian, S., Karantalis, V., Wolf, A., … & Valdes, D. (2015). Growth hormone–releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. Journal of the American Heart Association, 4(4), e001464.

Drugs.com (2015). Sermorelin acetate. https://www.drugs.com/cdi/sermorelin-acetate.html

World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2022. WADA website. January 1, 2022. Accessed Mar 2022. https://www.wada-ama.org/sites/default/files/resources/files/2022list_final_en.pdf

Baumann, G. P. (2012). Growth hormone doping in sports: a critical review of use and detection strategies. Endocrine Reviews, 33(2), 155-186.

Laron, Z. (1995). Growth hormone secretagogues. Drugs, 50(4), 595-601.

Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., and von Haehling, S. (2020) Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 3: 25– 37. https://doi.org/10.1002/rco2.9.

Chang Y, Huang R, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W, Hu H. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med 2021;9(5):406. doi: 10.21037/atm-20-6561.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosages

Sermorelin is administered through subcutaneous or intravenous injection, with dosages tailored to the patient’s age, condition, and treatment goals. For diagnostic purposes, such as evaluating growth hormone deficiency, clinicians typically administer a single dose of 1 mcg per kg of body weight intravenously. This stimulates the pituitary gland, allowing measurement of growth hormone release to assess pituitary function. In therapeutic settings, particularly for children with growth hormone deficiency, daily subcutaneous injections often range from 100 to 200 mcg, typically given at bedtime to align with the body’s natural growth hormone release cycle. Adult dosages, when used off-label to address growth hormone insufficiency, generally fall between 0.2 to 0.5 mg daily, adjusted based on clinical response and under medical supervision. Dosages require careful monitoring to ensure efficacy and safety, as user responses to sermorelin may vary.
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Human & Animal Studies

Human Studies Sermorelin and related GHRH(1-29) analogs have been studied in both children and adults. Clinical studies have evaluated sermorelin/GHRH therapy for: Growth hormone deficiency in children Idiopathic short stature or impaired growth velocity Diagnostic evaluation of GH reserve Age-related decline in GH secretion Effects on the somatotropic axis in older adults A review article describes sermorelin as a 29-amino-acid analog of human GHRH and the shortest synthetic peptide retaining full biologic activity of GHRH. In children with growth hormone deficiency, once-daily subcutaneous GHRH therapy was shown to accelerate growth during the first year of therapy. In older adults, nightly administration of a GHRH analog for four months activated the somatotropic axis, increasing GH and IGF-1 activity. Animal & Preclinical Studies Preclinical research on GHRH analogs has helped establish their biologic activity and receptor-mediated effects. Animal and laboratory studies have shown that GHRH analogs can: Stimulate pituitary GH release Increase downstream IGF-1 signaling Demonstrate receptor-specific activity at the GHRH receptor Support growth-related pathways Help characterize GH secretion physiology Animal and preclinical data support the biologic plausibility of sermorelin, but they do not establish safety or effectiveness for common off-label wellness uses in humans.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Sermorelin vs Ipamorelin

แม้ว่า เปปไทด์ ทั้งสองชนิดจะค่อนข้างคล้ายกันในแง่ของการทำงานสุดท้าย แต่ก็ยังมีความแตกต่างที่สำคัญในกลไกการออกฤทธิ์ Ipamorelin กระตุ้นต่อมใต้สมองในวิธีอื่น ๆ เพื่อการหลั่ง โกรทฮอร์…